Trial Profile

An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary)
Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions; Expanded access; Therapeutic Use
Sponsors Genentech

Most Recent Events

05 Jun 2018 Results (n=114) of an analysis assessing outcomes in patients with impaired baseline renal function or variant histology, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
06 Jun 2017 Interim safety results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
11 Aug 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com